Figure 5
Landmark analysis of the cumulative probability of OS according to the integrated mutational and cytogenetic model. (A) Diagnosis. (B) Landmark at 1 year. (C) Landmark at 2 years. (D) Landmark at 4 years. Patients harboring TP53 and/or BIRC3 disruption (TP53 DIS/BIRC3 DIS) independent of cooccurring genetic lesions are represented by the red line. Patients harboring NOTCH1 mutations (NOTCH1 M) and/or SF3B1 mutations (SF3B1 M) and/or del11q22-q23 in the absence of TP53 and BIRC3 disruption are represented by the yellow line. Patients harboring +12 in the absence of TP53 disruption, BIRC3 disruption, NOTCH1 mutations, SF3B1 mutations, and del11q22-q23 and patients wild-type for all genetic lesions (normal) are represented by the green line. Patients harboring del13q14 as the sole genetic lesion are represented by the blue line.

Landmark analysis of the cumulative probability of OS according to the integrated mutational and cytogenetic model. (A) Diagnosis. (B) Landmark at 1 year. (C) Landmark at 2 years. (D) Landmark at 4 years. Patients harboring TP53 and/or BIRC3 disruption (TP53 DIS/BIRC3 DIS) independent of cooccurring genetic lesions are represented by the red line. Patients harboring NOTCH1 mutations (NOTCH1 M) and/or SF3B1 mutations (SF3B1 M) and/or del11q22-q23 in the absence of TP53 and BIRC3 disruption are represented by the yellow line. Patients harboring +12 in the absence of TP53 disruption, BIRC3 disruption, NOTCH1 mutations, SF3B1 mutations, and del11q22-q23 and patients wild-type for all genetic lesions (normal) are represented by the green line. Patients harboring del13q14 as the sole genetic lesion are represented by the blue line.

Close Modal

or Create an Account

Close Modal
Close Modal